EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses

Yi-Lin Chiu, Tsai-Yuan Hsieh, Yu-Juei Hsu, Tien-Yu Huang, Chang-Hung Liao, Meng-Chuan Lu, Fang-Chen Liu, Yi-Ting Chou, Chao-Feng Chang, I-Hsuan Huang, Bao-Chung Chen, Hsuan-Hwai Lin und 3 weitere

Calcified Tissue International · 2025

DOI: 10.1007/s00223-025-01435-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Yi-Lin Chiu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department and Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Interferons, Bone and Bones. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Tri-Service General Hospital, Medical Affairs Bureau, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis C (CHC) is a risk factor for hepatic osteodystrophy, increasing osteoporosis and fracture risks. While historical pegylated interferon/ribavirin (PEG-IFN/RBV) showed variable bone effects, the newer direct-acting antivirals' (DAAs) impact is less clear. This study compared these antiviral strategies' effects on bone metabolism in CHC patients through two separate analyses. First, we conducted a retrospective analysis of a prospectively collected observational cohort (n = 73) to assess longitudinal bone mineral density (BMD) and bone turnover marker (BTM) changes following PEG-IFN/RBV or DAA therapies. Second, to explore mechanisms, we analyzed two independent, publicly available peripheral blood mononuclear cell (PBMC) transcriptomic cohorts from CHC patients treated with PEG-IFN/RBV (GSE7123, n = 69) or an IFN-free DAA regimen (GSE51699, n = 8). Clinically, PEG-IFN/RBV induced a temporary lumbar spine BMD increase, then a post-treatment decline, and modulated BTMs. DAAs showed minimal BMD/BTM effects. PBMC transcriptomics revealed PEG-IFN/RBV responders showed downregulation of osteoclast precursor (OCP)-related gene sets and concurrent upregulation of osteoblast-related gene sets. DAAs had a minimal impact on these PBMC pathways. These findings demonstrate distinct effects of PEG-IFN/RBV and DAA therapies. PEG-IFN/RBV significantly modulates PBMC gene expression related to bone remodeling, potentially contributing to the complex clinical BMD changes, while DAAs appear largely bone-neutral. This highlights treatment-specific osteoporosis risk and surveillance needs in CHC survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis C, ChronicInterferonsBone and BonesHumansMaleFemaleMiddle AgedBone DensityAdultRibavirinRetrospective StudiesTranscriptomeBone RemodelingAgedInterferon-alphaProspective Studies

Stichwörter der Autor:innen

Bone mineral densityChronic hepatitis CDirect-acting antiviralsInterferon therapyOsteoimmunologyTranscriptomics

Substanzen

Antiviral AgentsInterferonsRibavirinInterferon-alpha

Autor:innen und Institutionen

  • Department and Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • Institute of Preventive Medicine, National Defense Medical University, Taipei, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung, Taiwan.
  • Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.

ORCID-Profile: Jung-Chun Lin

Förderung

  • Tri-Service General Hospital
  • Medical Affairs Bureau
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Chiu, Y. L., Hsieh, T. Y., Hsu, Y. J., Huang, T. Y., Liao, C. H., Lu, M. C., Liu, F. C., Chou, Y. T., Chang, C. F., Huang, I. H., Chen, B. C., Lin, H. H., Shih, Y. L., Yang, Y. J., & Lin, J. C. (2025). Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01435-0

Vancouver

Chiu YL, Hsieh TY, Hsu YJ, Huang TY, Liao CH, Lu MC, et al. Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01435-0

BibTeX
@article{Chiu2025,
  author = {Chiu, Yi-Lin and Hsieh, Tsai-Yuan and Hsu, Yu-Juei and Huang, Tien-Yu and Liao, Chang-Hung and Lu, Meng-Chuan and Liu, Fang-Chen and Chou, Yi-Ting and Chang, Chao-Feng and Huang, I-Hsuan and Chen, Bao-Chung and Lin, Hsuan-Hwai and Shih, Yu-Lueng and Yang, Yun-Ju and Lin, Jung-Chun},
  title = {Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses},
  journal = {Calcified Tissue International},
  year = {2025},
  doi = {10.1007/s00223-025-01435-0}
}
Kostenlos starten →